{"id":"arbidol","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL1214598","moleculeType":"Small molecule","molecularWeight":"477.42"},"aliases":["Arbidol Hydrochloride","The basic treatment used by the investigator was based on the condition of the patient"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Hemagglutinin [Cleaved into: Hemagglutinin HA1 chain; Hemagglutinin HA2 chain]"},"_scrapedAt":"2026-03-28T00:17:45.252Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Influenza","diseaseId":"influenza","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03851991","phase":"PHASE4","title":"The Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD.","status":"COMPLETED","sponsor":"Shengjing Hospital","startDate":"2019-08-30","conditions":"COPD Patients","enrollment":351},{"nctId":"NCT03787459","phase":"PHASE3","title":"Severe Influenza Trial of ARbidol","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2019-01-18","conditions":"Influenza","enrollment":200},{"nctId":"NCT06462417","phase":"NA","title":"Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis","status":"RECRUITING","sponsor":"Zheng Liu","startDate":"2024-07-11","conditions":"Allergic Rhinitis","enrollment":15},{"nctId":"NCT06286254","phase":"","title":"Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2023-09-20","conditions":"Acute Respiratory Viral Infection","enrollment":742},{"nctId":"NCT05783206","phase":"PHASE2, PHASE3","title":"Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Mild COVID-19","status":"COMPLETED","sponsor":"National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia","startDate":"2022-02-10","conditions":"COVID-19","enrollment":984},{"nctId":"NCT04664010","phase":"NA","title":"Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19)","status":"COMPLETED","sponsor":"Xi'an International Medical Center Hospital","startDate":"2020-02-06","conditions":"COVID-19","enrollment":30},{"nctId":"NCT04260594","phase":"PHASE4","title":"Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus","status":"COMPLETED","sponsor":"Jieming QU","startDate":"2020-02-08","conditions":"2019-nCoV","enrollment":236},{"nctId":"NCT04476719","phase":"PHASE1","title":"The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions","status":"UNKNOWN","sponsor":"Atabay Kimya Sanayi Ticaret A.S.","startDate":"2020-07-09","conditions":"Bioequivalence","enrollment":18},{"nctId":"NCT04252885","phase":"PHASE4","title":"The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection","status":"COMPLETED","sponsor":"Guangzhou 8th People's Hospital","startDate":"2020-01-28","conditions":"Coronavirus Infections","enrollment":86},{"nctId":"NCT04306497","phase":"","title":"TCM Differentiation and Treatment Protocol of COVID-19","status":"COMPLETED","sponsor":"Jiangsu Famous Medical Technology Co., Ltd.","startDate":"2020-01-22","conditions":"COVID-19","enrollment":340},{"nctId":"NCT04273763","phase":"NA","title":"Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-02-16","conditions":"Novel Coronavirus Pneumonia, 2019-nCoV","enrollment":18},{"nctId":"NCT04333589","phase":"NA","title":"Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2020-04-01","conditions":"COVID-19","enrollment":210},{"nctId":"NCT04323345","phase":"PHASE3","title":"Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus","status":"UNKNOWN","sponsor":"Misr University for Science and Technology","startDate":"2020-04-15","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT04350684","phase":"PHASE4","title":"Umifenovir in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-15","conditions":"COVID-19","enrollment":40},{"nctId":"NCT04286503","phase":"PHASE4","title":"The Clinical Study of Carrimycin on Treatment Patients With COVID-19","status":"UNKNOWN","sponsor":"Beijing YouAn Hospital","startDate":"2020-02-23","conditions":"Novel Coronavirus Infectious Disease (COVID-19)","enrollment":520},{"nctId":"NCT01651663","phase":"PHASE4","title":"A Study of Arbidol (Umifenovir) for Treatment and Prophylaxis of Influenza and Common Cold","status":"UNKNOWN","sponsor":"Pharmstandard","startDate":"2011-09","conditions":"Influenza","enrollment":840}],"_emaApprovals":[],"_faersSignals":[{"count":154,"reaction":"OFF LABEL USE"},{"count":26,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":16,"reaction":"DIARRHOEA"},{"count":14,"reaction":"PRODUCT USE ISSUE"},{"count":11,"reaction":"MATERNAL EXPOSURE DURING PREGNANCY"},{"count":10,"reaction":"DRUG EFFECTIVE FOR UNAPPROVED INDICATION"},{"count":10,"reaction":"PYREXIA"},{"count":9,"reaction":"PNEUMONIA"},{"count":9,"reaction":"VOMITING"},{"count":7,"reaction":"DYSPNOEA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Arbidol","genericName":"Arbidol","companyName":"Zheng Liu","companyId":"zheng-liu","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}